Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

AIM: This study investigated the effects of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban (10 mg), an oral, direct Factor Xa inhibitor. METHOD: This single centre, non-randomized, non-blinded study included subjects with mild (n = 8) or moderate hepa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kubitza, Dagmar, Roth, Angelika, Becka, Michael, Alatrach, Abir, Halabi, Atef, Hinrichsen, Holger, Mueck, Wolfgang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Science Inc 2013
Gaiak:
Pharmacokinetics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703231/
https://ncbi.nlm.nih.gov/pubmed/23294275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12054
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak